Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review

References

• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–479.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70:256–262.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387:1163–1177.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746.
   PubMed Web of Science ®Google Scholar
• Berg KD, Roder MA, Thomsen FB, et al. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. Prostate. 2015;75:1499–1509.
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
   PubMed Web of Science ®Google Scholar
• Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–228.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–1259.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930–942.
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659.
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–970.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–341.
   PubMed Web of Science ®Google Scholar
• Kadmon D, Heston WD, Fair WR. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol. 1982;127:1238–1242.
   PubMed Web of Science ®Google Scholar
• Cifuentes FF, Valenzuela RH, Contreras HR, et al. Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer. Oncol Rep. 2015;34:2837–2844.
   PubMed Web of Science ®Google Scholar
• Overview of the SEER Program. [cited 2017 Jun 1]. Available from: http://seer.cancer.gov/about/overview.
   Google Scholar
• Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65:1058–1066.
   PubMed Web of Science ®Google Scholar
• Antwi S, Everson TM. Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol. 2014;38:435–441.
   PubMed Web of Science ®Google Scholar
• Fossati N, Trinh QD, Sammon J, et al. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015;67:3–6.
   PubMed Web of Science ®Google Scholar
• Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol. 2015;194:378–385.
   PubMed Web of Science ®Google Scholar
• Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34:2835–2842.
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ. 2014;348:g1502.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66:602–603.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193:832–838.
   PubMed Web of Science ®Google Scholar
• Predina JD, Kapoor V, Judy BF, et al. Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J Hematol Oncol. 2012;5:34.
   PubMed Web of Science ®Google Scholar
• Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol. 2011;8:369–377.
   PubMed Web of Science ®Google Scholar
• Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011; 29:2574–2581.
   PubMed Web of Science ®Google Scholar
• Jespersen CG, Norgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65:704–709.
   PubMed Web of Science ®Google Scholar
• Fall K, Stromberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol. 2008;42:352–357.
   PubMed Web of Science ®Google Scholar
• Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164–169.
   PubMed Web of Science ®Google Scholar
• Aydemir H, Kumsar S. Re: Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study: A. Heidenreich, D. Pfister and D. Porres. J Urol. 2015;193:832–838. J Urol 2015; 194:853-855.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Bennett CL, Andriole GL, et al. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013;112:548–560.
   PubMed Web of Science ®Google Scholar
• Tomioka A, Tanaka N, Yoshikawa M, et al. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol. 2014;14:33
   PubMed Web of Science ®Google Scholar
• Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol. 2016;69:788–794.
   PubMed Web of Science ®Google Scholar
• Tewari A, Sooriakumaran P, Bloch DA, et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012;62:1–15.
   PubMed Web of Science ®Google Scholar
• Gontero P, Marchioro G, Pisani R, et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol. 2007;51:922–929. discussion 929–930.
   PubMed Web of Science ®Google Scholar
• Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol. 1995;154:466–469.
   PubMed Web of Science ®Google Scholar
• Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112:E250–E255.
   PubMed Web of Science ®Google Scholar
• Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ. 2010;13:351–361.
   PubMedGoogle Scholar
• Steinberg GD, Epstein JI, Piantadosi S, et al. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol. 1990;144:1425–1432.
   PubMed Web of Science ®Google Scholar
• Martini-Klinik am UKE GmbH. Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases (g-RAMPP). ClinicalTrials.gov Identifier: NCT02454543.
   Google Scholar
• University Hospital, Ghent. Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa). ClinicalTrials.gov Identifier: NCT02138721.
   Google Scholar
• Medical Research Council. STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial. ClinicalTrials.gov Identifier: NCT00268476.
   Google Scholar
• M.D. Anderson Cancer Center. Best systemic therapy or best systemic therapy (BST) plus definitive treatment (radiation or surgery). ClinicalTrials.gov Identifier: NCT01751438.
   Google Scholar
• Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer. ClinicalTrials.gov Identifier: NCT02971358.
   Google Scholar
• Raziee H, Moraes FY, Murgic J, et al. Improved outcome in localized prostate cancer treated with precision image-guided radiotherapy. Radiother Oncol. 2017; pii: S0167-8140:30143–30143. [Epub ahead of print]
   Google Scholar
• Kalbasi A, Li J, Berman A, et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol. 2015;1:897–906.
   PubMed Web of Science ®Google Scholar